Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds

被引：31

作者：

Smith, Kenneth J. ^{[1
]}

Lee, Bruce Y. ^{[1
]}

Nowalk, Mary Patricia ^{[1
]}

Raymund, Mahlon ^{[1
]}

Zimmerman, Richard K. ^{[1
]}

机构：

[1] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA

来源：

VACCINE | 2010年 / 28卷 / 48期

关键词：

Pneumococcal polysaccharide vaccine; Influenza vaccine; Cost-effectiveness; Secondary pneumococcal pneumonia; POLYSACCHARIDE VACCINE; OLDER-ADULTS; REVACCINATION; DISEASE; CONJUGATE; EFFICACY; SAFETY;

D O I：

10.1016/j.vaccine.2010.09.053

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Influenza vaccination is now recommended for all ages; CDC pneumococcal polysaccharide vaccination (PPV) recommendations are comorbidity-based in nonelderly patients. We constructed a Markov model to estimate the cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Patients were followed for 10 years, with differing time horizons examined in sensitivity analyses. With 100% vaccine uptake, dual vaccination cost $37,700/QALY gained compared to a CDC recommendation strategy; with observed vaccine uptake, dual vaccination cost $5,300/QALY. Results were sensitive to shorter time horizons, favoring CDC recommendations. We found dual vaccination of all 50-year-olds economically reasonable. Shorter duration models may not fully account for PPV effectiveness. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：7620 / 7625

页数：6

共 29 条

[1]

[Anonymous], 1996, COST EFFECTIVENESS H, DOI DOI 10.1093/OSO/9780195108248.001.0001

[2]

[Anonymous], 2010, CTR DIS CONTR PREV N

[3] What does the value of modern medicine say about the $50,000 per Quality-Adjusted Life-Year decision rule? [J].

Braithwaite, R. Scott ;

Meltzer, David O. ;

King, Joseph T., Jr. ;

Leslie, Douglas ;

Roberts, Mark S. .

MEDICAL CARE, 2008, 46 (04) :349-356

[4]

*CDCP, 2010, ACIP PROV REC US INF

[5]

*CDCP, 2008, SELF REP PNEUM VACC

[6]

Centers for Disease Control and Prevention, 2008, SELF REP INFL VACC C

[7] IMMUNOGENICITY OF PNEUMOCOCCAL REVACCINATION IN PATIENTS WITH CHRONIC DISEASE [J].

DAVIDSON, M ;

BULKOW, LR ;

GRABMAN, J ;

PARKINSON, AJ ;

CHAMBLEE, C ;

WILLIAMS, WW ;

LANIER, AP ;

SCHIFFMAN, G .

ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (19) :2209-2214

[8] PNEUMOCOCCAL VACCINE - EFFICACY AND ASSOCIATED COST SAVINGS [J].

GABLE, CB ;

HOLZER, SS ;

ENGELHART, L ;

FRIEDMAN, RB ;

SMELTZ, F ;

SCHROEDER, D ;

BAUM, K .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (22) :2910-2915

[9] Toward consistency in cost-utility analyses - Using national measures to create condition-specific values [J].

Gold, MR ;

Franks, P ;

McCoy, KI ;

Fryback, DG .

MEDICAL CARE, 1998, 36 (06) :778-792

[10]

IOM Report, 2005, ACAD EMERG MED, V12, P1011

← 1 2 3 →